best peptides FAQ

Verify product purity first. If you're using unverified BPC-157, you may be injecting degraded or incorrectly sequenced peptide that won't bind to growth factor receptors. Switch to a supplier with third-party HPLC verification. If purity isn't the issue, confirm you're dosing at least 200 mcg twice daily. Single daily doses or under-dosing below 200 mcg total often fail to reach therapeutic thresholds. BPC-157's half-life is 4–6 hours, so split dosing maintains more consistent plasma levels throughout the day. Injection site proximity to the injury increases local concentration but isn't required. Systemic subcutaneous administration still produces effects.

Document explicitly that the prescription is being written off-label for performance rather than metabolic disease or injury recovery, and ensure your state medical board permits off-label peptide prescribing under telemedicine statutes. Several states (Texas, Florida, Arizona) allow broad off-label prescribing discretion; others (California, New York) require documented medical necessity. If your state restricts off-label peptide use, refer the patient to a clinician licensed in a jurisdiction with more permissive regulations rather than risk board action.

Use MOTS-C at 5–10mg once weekly during your base training phase (8–12 weeks minimum). MOTS-C enhances mitochondrial efficiency and shifts substrate preference toward fat oxidation at sub-threshold intensities. The effect is cumulative and shows measurable improvement in respiratory exchange ratio after 4–6 weeks of consistent dosing. Inject subcutaneously in the morning on non-training days. Pair it with Zone 2 training at 60–70% FTP for 3–4 hours weekly to maximise mitochondrial adaptation. Don't expect acute changes. This is a structural adaptation tool, not a race-day enhancer. The Fat Loss Metabolic Health Bundle from Real Peptides pairs MOTS-C with complementary compounds that support metabolic flexibility during endurance training blocks.

If fewer than 10 days have passed since the last scheduled dose, administer the missed dose immediately and resume the regular weekly schedule. If more than 10 days have passed, restart at the previous titration step (one dose level lower) and re-escalate over four weeks. Jumping back to the prior dose after a prolonged gap significantly increases nausea and vomiting risk because gastric adaptation to GLP-1 agonism fades within 14 days of the last injection.

MK-677 activates ghrelin receptors, which is why it increases GH but also stimulates hunger. This is mechanism-inherent, not avoidable. Structure your eating window around the ghrelin spike: dose MK-677 at night, then don't eat for at least 10–12 hours post-dose. This aligns appetite increases with fasting periods when you're asleep. Alternatively, pair MK-677 with a peptide that improves satiety signaling, like a GLP-1 analog, but be aware that stacking peptides increases complexity. If appetite management becomes unworkable, switch to a pulsatile GH protocol using GHRP-2 or CJC-1295 instead. These don't activate ghrelin receptors as aggressively.

Physically possible but not advisable. The peptides have different solubility profiles and reconstitution concentrations. BPC-157 is typically prepared at 5 mg/mL while TB-500 requires 2 mg/mL due to its larger molecular weight. Mixing them in one syringe creates an unpredictable concentration gradient that may reduce effective dose at the injection site. More importantly, their mechanisms target overlapping but distinct pathways: separating injections by 4–6 hours allows each peptide's receptor binding to occur without competitive inhibition at the cellular level.

Stop climbing immediately and start BPC-157 at 250–500 mcg/day injected subcutaneously near the base of the affected finger. The first 72 hours post-injury are the acute inflammatory phase. Ice, compression, and complete rest are still required. Begin passive range-of-motion exercises (flexion/extension with no load) on day 3–4. BPC-157 accelerates the transition from the inflammatory phase to the proliferative phase, where new collagen is laid down. You're looking at 10–14 days before you can reintroduce light crimping with resistance bands at 30–40% max effort. Full return to max-grade bouldering typically takes 8–10 weeks even with peptides. Rushing this timeline increases re-injury risk dramatically.

That's a clinical decision that supersedes any protocol outlined here. Some surgeons restrict peptide use due to concerns about accelerated angiogenesis in specific surgical contexts. For example, after tumour excision where residual malignant cells could theoretically exploit new blood vessel formation. Others cite lack of Phase 3 human trial data, which is accurate: most peptide research exists in animal models or observational case series rather than randomised controlled trials. If your prescriber is unfamiliar with the peptides' mechanisms, sharing the specific studies cited here (Journal of Physiology and Pharmacology for BPC-157, Annals of the New York Academy of Sciences for TB-500) may provide the clarity needed for an informed decision.

Headaches from Semax typically indicate improper reconstitution or overly concentrated solution. Research protocols use 0.1% concentration (1mg Semax per 1mL bacteriostatic water). Higher concentrations irritate nasal mucosa and trigger vascular headaches. If using a pre-mixed nasal spray, ensure it's pharmacy-grade. Contaminated or improperly pH-balanced formulations cause inflammatory responses. Switching to a verified source like Real Peptides eliminates this issue in most cases.

Discard the vial immediately and ship a replacement. Cloudiness indicates bacterial contamination or protein aggregation. Both render the peptide ineffective and potentially unsafe. Lyophilised peptides should produce a clear, colourless solution when reconstituted with bacteriostatic water; any turbidity, discolouration, or visible particulate means the compound has degraded. The most common cause is injecting air into the vial during reconstitution, which creates positive pressure that draws contaminants back through the needle.

Lyophilized peptides in powder form are stable at room temperature for several weeks if kept below 25°C and away from light and moisture. Once reconstituted with bacteriostatic water, peptides require refrigeration at 2–8°C and should be used within 28 days. For travel, use an insulin cooler or FRIO wallet. These maintain 2–8°C for 36–48 hours without electricity using evaporative cooling. If you're traveling for longer than 48 hours, either bring lyophilized powder and reconstitute on-site, or accept that peptide efficacy degrades with temperature excursions above 8°C. Peptides exposed to heat don't necessarily look different, but protein denaturation is irreversible.

Yes, but the benefit scales with training volume. Athletes sleeping 8+ hours and eating in a caloric surplus already have optimised endogenous GH production. Adding a growth hormone secretagogue amplifies that baseline, shortening recovery windows between high-volume blocks. The practical difference: an athlete might handle five training days weekly without peptides but sustain six days with a secretagogue, or maintain intensity across a second daily session that would otherwise require backing off. The mechanism works whether you're starting from optimal or suboptimal baselines. It's simply additive.

Layer peptides sequentially based on mechanism priority rather than stacking simultaneously. Start with metabolic or immune foundation (MOTS-c or thymosin alpha-1), run for 4–6 weeks to establish baseline response, then add tissue repair peptides (BPC-157) if indicated. Stacking more than two peptides initially makes it impossible to identify which compound is producing effects or causing side effects. Practitioners lose diagnostic clarity.

Verify injection timing relative to meals. Insulin elevation from carbohydrate intake within 90 minutes before or after GHRP administration suppresses GH release by 60–80%. Dose GHRP-2 at true fasting windows: upon waking before food, mid-afternoon at least 3 hours post-lunch, and 2+ hours after dinner before bed. If timing is correct and effects remain absent, the issue is either peptide degradation (check reconstitution date and storage temperature) or dose insufficiency (increase from 100mcg to 200mcg per injection and reassess after one week).

Administer the missed dose as soon as you remember if fewer than 3 days have passed since your scheduled injection, then resume your regular twice-weekly schedule. If more than 3 days have passed, skip the missed dose and continue on your next scheduled date. Do not double-dose to compensate. TB-500 has a half-life of approximately 10 days, so missing one dose doesn't eliminate systemic coverage entirely, but consistency matters for maintaining stable tissue repair signaling. If you're traveling frequently, consider pre-loading single-use syringes at home and storing them in a portable medication cooler to reduce preparation errors on the road.

BPC-157 targets localised tissue repair more directly than systemic GH secretagogues. Dose 250–500mcg subcutaneously near the affected joint once or twice daily for 4–8 weeks. Pair it with TB-500 if range of motion is limited or scar tissue is present. TB-500's actin-binding mechanism prevents fibrosis and improves tissue extensibility. A GH secretagogue like MK-677 can run concurrently to support systemic collagen synthesis, but the tissue repair peptides address the injury site directly.

Preventative peptide use is less researched than acute injury protocols, but growth-hormone secretagogues like Ipamorelin or MK-677 make sense here. Ipamorelin dosed at 200 mcg before bed for 12-week cycles creates a sustained elevation in IGF-1 without the side effects of exogenous GH. This supports collagen turnover, bone density, and muscle recovery during phases where training volume exceeds your natural recovery capacity. The Healing Total Recovery Bundle is designed for exactly this use case. Maintaining tissue health under chronic load.

Hold the current dose for an additional four weeks before advancing to the next titration step. GI side effects peak during the first four weeks at each new dose because GLP-1 receptor density in the gut exceeds hypothalamic receptor density. The nausea reflects gastric emptying delay, not systemic toxicity. If nausea persists beyond eight weeks at the same dose, consider switching to a 0.125mg microdose increment rather than the standard 0.25mg step, or pause escalation entirely and maintain at the current dose if the patient is achieving meaningful weight reduction.

Chronic medial epicondylitis is an overuse injury driven by repetitive eccentric loading of the forearm flexors. It's not an acute tear, so BPC-157 alone may not address the underlying tissue degradation. TB-500 at loading-phase dosing (2–5 mg twice weekly for 6 weeks) works better for chronic inflammation because it promotes systemic tissue remodeling. Pair TB-500 with eccentric wrist flexor exercises using a light dumbbell. 3 sets of 15 reps, 3 times per week. The eccentric load signals the body to rebuild the tendon stronger. TB-500 accelerates that process. Most climbers report 50–70% reduction in pain under load by week 4–5.

Inject BPC-157 at 250–500mcg subcutaneously near the patellar tendon insertion twice daily for 4–6 weeks. The peptide works locally by increasing vascular endothelial growth factor expression at the injury site, which accelerates collagen turnover and reduces pain within 10–14 days in most cases. Pair it with eccentric loading protocols (slow tempo squats, declining single-leg work). BPC-157 accelerates tissue remodeling but doesn't replace mechanical stimulus. If pain persists beyond 6 weeks, consider adding TB-500 at 2mg twice weekly for broader systemic anti-inflammatory coverage, particularly if you're also managing hip or lower back stiffness from compensatory movement patterns.